Complement Factor H Autoantibodies and Age-Related Macular Degeneration

Baljean Dhillon, Alan F. Wright, Adnan Tufail, Isabel Pappworth, Caroline Hayward, Iain Moore, Lisa Strain, David Kavanagh, Paul N. Barlow, Andrew P. Herbert, Christoph Q. Schmidt, Ana-Maria Armbrecht, Augustinus Laude, Ian J. Deary, Scott J. Staniforth, Lucy V. Holmes, Timothy H. J. Goodship, Kevin J. Marchbank

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Purpose. In this case-control study, the hypothesis that factor H autoantibodies are associated with age-related macular degeneration (AMD) was examined.

Methods. One hundred AMD patients (median age, 78 years), 98 age-matched control subjects (median age, 78 years) known not to have AMD, and 100 healthy blood donors (median age, 43 years) were enrolled. An enzyme-linked immunosorbent assay (ELISA) was used to screen for complement factor H autoantibodies and either quantitative polymerase chain reaction (qPCR) or multiplex ligation–dependent probe amplification (MLPA) were performed to measure the copy number of the gene encoding complement factor H–related protein 3 (CFHR3).

Results. There was a significant difference in the median complement factor H autoantibody titer between the three groups (AMD patients, 196 reference units [RU]]; age-match control subjects, 316 RU; and blood donor control subjects, 121 RU; Kruskal-Wallis test, P < 0.001). Pair-wise comparison (Mann-Whitney test) showed that all three groups were significantly different from each other. Two different thresholds were used in the healthy blood donors to identify individuals with complement factor H autoantibodies. Both suggested that the prevalence of factor H autoantibodies was decreased in AMD patients. The CFHR3 copy number was measured as a surrogate for the deletion of the genes encoding complement factor H–related proteins 3 and 1 (CFHR3/1). The allele frequency of the deletion was significantly higher in the age-matched control subjects than in the AMD patients (22.2% vs. 8.2%).

Conclusions. The level of factor H autoantibodies is lower in AMD patients than in age-matched control subjects.
Original languageEnglish
Pages (from-to)5858-5863
Number of pages6
JournalInvestigative Ophthalmology & Visual Science (IOVS)
Issue number11
Publication statusPublished - Nov 2010


Dive into the research topics of 'Complement Factor H Autoantibodies and Age-Related Macular Degeneration'. Together they form a unique fingerprint.

Cite this